Faecal calprotectin levels after rifaximin treatment in patients with irritable bowel syndrome with diarrhoea: A single-center prospective study
- 12 September 2020
- journal article
- research article
- Published by Elsevier BV in Arab Journal of Gastroenterology
- Vol. 21 (4), 273-277
- https://doi.org/10.1016/j.ajg.2020.08.003
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndromeMolecular Medicine Reports, 2014
- The Role of Rifaximin in the Primary Prophylaxis of Spontaneous Bacterial Peritonitis in Patients With Liver CirrhosisJournal of Clinical Gastroenterology, 2012
- Benefits from Long-Term Treatment in Irritable Bowel SyndromeGastroenterology Research and Practice, 2012
- Meta-analysis: long-term therapy with rifaximin in the management of uncomplicated diverticular diseaseAlimentary Pharmacology & Therapeutics, 2011
- Rifaximin Therapy for Patients with Irritable Bowel Syndrome without ConstipationThe New England Journal of Medicine, 2011
- Rifaximin modulates the colonic microbiota of patients with Crohn's disease: an in vitro approach using a continuous culture colonic model systemJournal of Antimicrobial Chemotherapy, 2010
- Small Intestinal Bacterial Overgrowth in Irritable Bowel Syndrome: Systematic Review and Meta-analysisClinical Gastroenterology and Hepatology, 2009
- The endogenous Toll–like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancerJournal of Leukocyte Biology, 2009
- The Effect of a Nonabsorbed Oral Antibiotic (Rifaximin) on the Symptoms of the Irritable Bowel SyndromeAnnals of Internal Medicine, 2006
- Rifaximin for active ulcerative colitisInflammatory Bowel Diseases, 2006